南新制药拟“掏空家底”收购相关资产组，押宝多种微量元素注射液

Core Viewpoint - Hunan Nanxin Pharmaceutical Co., Ltd. plans to acquire assets from Future Pharmaceuticals for up to 480 million yuan, aiming to enhance its product pipeline and address ongoing financial losses [1][2]. Group 1: Acquisition Details - The acquisition includes three types of microelement injection solutions, which are already listed and have established market sales, potentially providing immediate revenue and profit growth for the company [1][2]. - The assets also encompass a mature nationwide sales channel and academic promotion system, which could facilitate market access for the company's products [2]. Group 2: Financial Performance - Nanxin Pharmaceutical has reported continuous losses for four consecutive years since its IPO, with revenues declining significantly from 1.029 billion yuan in 2020 to 263 million yuan in 2024 [4][5]. - The company's net profit has also been negative in recent years, with a reported loss of 357 million yuan in 2024 [4]. - In Q1 2025, the company experienced a 70.21% year-on-year decline in revenue, amounting to 40.62 million yuan, and a net loss of 8.03 million yuan, a 143.66% increase in losses compared to the previous year [5]. Group 3: Market Competition - The company's main product, Palivizumab Sodium Injection, has faced increased competition, leading to a price reduction of 43.51% in 2023 and further price cuts planned for 2024 [3][4]. - Despite these price adjustments, the performance of the core product has not improved, contributing to the overall decline in financial results [4].